607 Results

People

  1. Shukla
    Shukla
  2. Steinherz
    Steinherz
  3. Trippett
    Trippett
  4. Kentsis
    Kentsis
  5. Forlenza
    Forlenza
  6. Ladanyi
    Ladanyi
  7. Sulis
    Sulis
  8. O'Reilly
    O'Reilly
  9. Cifani
    Cifani
  10. Kernan
    Kernan

Groups

  1. Hematologic Malignancies Service (607)
  2. Pediatrics, Department of (607)
  3. Center for Hematologic Malignancies (554)
  4. Pediatric Leukemia (455)
  5. GSK Faculty (220)
  6. Tow Center for Developmental Oncology (TCDO) (206)
  7. Sloan Kettering Institute Faculty (148)
  8. Department of Medicine (147)
  9. Hematologic Malignancies Research (114)
  10. Molecular Pharmacology and Chemistry Program Faculty (114)
  1. "Hematologic Malignancies Service"
Formats
  1. Journal Article (349)
  2. Meeting Abstract (232)
  3. Review (11)
  4. Research Letter (5)
  5. Editorial (4)
  6. Book Section (2)
  7. Conference Paper (2)
  8. Correspondence (1)
  9. Guidelines (1)
Groups
  1. Hematologic Malignancies Service (607)
  2. Pediatrics, Department of (607)
  3. Center for Hematologic Malignancies (554)
  4. Pediatric Leukemia (455)
  5. GSK Faculty (220)
  6. Tow Center for Developmental Oncology (TCDO) (206)

More Groups

People
  1. Peter Steinherz (221)
  2. Neerav Shukla (159)
  3. Tanya Trippett (126)
  4. Alex Kentsis (103)
  5. Christopher Forlenza (49)
  6. Marc Ladanyi (44)

More People

Years
  1. 2025 (11)
  2. 2024 (27)
  3. 2023 (37)
  4. 2022 (34)
  5. 2021 (29)
  6. 2020 (29)

More Years

Publications
  1. Blood (125)
  2. Journal of Clinical Oncology (61)
  3. Pediatric Blood and Cancer (57)
  4. Cancer Research (22)
  5. Cancer (18)
  6. Journal of Pediatric Hematology/Oncology (16)

More Publications

Publishers
  1. American Society of Hematology (134)
  2. American Society of Clinical Oncology (69)
  3. Wiley Periodicals, Inc (57)
  4. American Association for Cancer Research (56)
  5. Nature Publishing Group (39)
  6. Elsevier Inc. (33)

More Publishers

Results (607)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic (ALL)
    Meeting Abstract

    Gore, L.; Zugmaier, G.; Handgretinger, R.; Locatelli, F.; Trippett, T. M.; Rheingold, S. R.; Bader, P.; Borkhardt, A.; Cooper, T. M.; O'Brien, M. M.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase 1/2 study of blinatumomab in pediatric patients with relapsed/refractory B-cell precursor acute lymphoblastic leukemia
    Meeting Abstract

    von Stackelberd, A.; Zugmaier, G.; Handgretinger, R.; Locatelli, F.; Rizzari, C.; Trippett, T. M.; Borkhardt, A.; Rheingold, S. R.; Bader, P.; Bhojwani, D.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Targeting oncogenic interleukein-7 receptor signaling with N-acetylcysteine in T-cell acute lymphoblastic leukemia
    Meeting Abstract

    Mansour, M. R.; Reed, C.; Eisenberg, A.; Tseng, J. C.; Yoda, A.; Rodig, S. J.; DeAngelo, D. J.; Sallan, S. E.; Weinstock, D. M.; Izraeli, S.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • In vitro growth inhibition, target modulation and drug synergy in pediatric leukemia by the novel proteasome inhibitor carfilzomib
    Meeting Abstract

    Jayanthan, A.; Ruan, Y.; Hagerty, M.; Shah, R.; Truong, T.; Lewis, V. A.; Boklan, J.; Trippett, T.; Gore, L.; Narendran, A.
    Blood (2013)

    Fulltext@MSK | Save
  • Chemosensitization and mobilization of AML/ALL/MDS with plerixafor (AMD 3100), a CXCR4 antagonist: A phase I study of plerixafor + cytarabine and etoposide in pediatric patients with acute leukemia and MDS
    Meeting Abstract

    Cooper, T. M.; Baker, S. D.; Direnzo, J.; Trippett, T. M.; Gore, L.; Narendran, A.; August, K. J.; Absalon, M. J.; Boklan, J.; Pollard, J.; more...
    Blood (2013)

    Fulltext@MSK | Save
  • Biomarkers in Ewing sarcoma: The promise and challenge of personalized medicine. A report from the children's oncology group
    Journal Article

    Shukla, N.; Schiffman, J. D.; Reed, D.; Davis, I. J.; Womer, R. B.; Lessnick, S. L.; Lawlor, E. R.
    Frontiers in Oncology (2013)

    Fulltext@MSK | Save
  • Cytological and molecular remissions with blinatumomab treatment in second or later bone marrow relapse in pediatric acute lymphoblastic leukemia (ALL)
    Meeting Abstract

    Von Stackelberg, A.; Zugmaier, G.; Handgretinger, R.; Locatelli, F.; Trippett, T. M.; Rheingold, S. R.; Bader, P.; Borkhardt, A.; Cooper, T. M.; Obrien, M. M.; more...
    Pediatric Blood and Cancer (2013)

    Fulltext@MSK | Save
  • A prospective multi-institutional phase II study of everolimus (Rad001), an mtor inhibitor, in pediatric patients with recurrent or progressive low-grade glioma. A poetic consortium trial
    Meeting Abstract

    Kieran, M.; Yao, X.; Macy, M.; Geyer, R.; Cohen, K.; MacDonald, T.; Allen, J.; Boklan, J.; Smith, A.; Nazemi, K.; more...
    Pediatric Blood and Cancer (2013)

    Fulltext@MSK | Save
  • Ten-year follow-up of pediatric patients with non-hodgkin lymphoma treated with allogeneic or autologous stem cell transplantation
    Journal Article

    Giulino-Roth, L.; Ricafort, R.; Kernan, N. A.; Small, T. N.; Trippett, T. M.; Steinherz, P. G.; Prockop, S. E.; Scaradavou, A.; Chiu, M.; O'Reilly, R. J.; more...
    Pediatric Blood and Cancer (2013)

    Fulltext@MSK | Save
  • Pathology turnaround time in pediatric oncology: A tool to prepare patients and families for the diagnostic waiting period
    Journal Article

    Forlenza, C. J.; Levy, A. S.
    Journal of Pediatric Hematology/Oncology (2013)

    Fulltext@MSK | Save